Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
19,417
Total Claims
$1.2M
Drug Cost
347
Beneficiaries
$3,374
Cost/Patient
Risk Score Breakdown 47/100
Score components are additive. Read full methodology
Peer Comparison vs. 5,387 Infectious Disease providers
-58%
Cost per patient vs peers
$3,374 vs $8,010 avg
+11%
Brand preference vs peers
23.5% vs 21.3% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
6.9%
Opioid Rate
1,338
Opioid Claims
$18K
Opioid Cost
7.1%
Long-Acting Rate
Brand vs Generic
Brand: 4,552 claims · $857K
Generic: 14,810 claims · $313K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,629 | $250K |
| Rivaroxaban | 343 | $55K |
| Insulin Aspart | 203 | $43K |
| Sitagliptin Phosphate | 279 | $39K |
| Fluticasone/Vilanterol | 90 | $38K |
| Sacubitril/Valsartan | 218 | $35K |
| Insulin Glargine,hum.Rec.Anlog | 118 | $32K |
| Insulin Detemir | 81 | $30K |
| Empagliflozin | 160 | $24K |
| Dapagliflozin Propanediol | 156 | $23K |
| Fluticasone/Umeclidin/Vilanter | 31 | $21K |
| Insulin Glargine,hum.Rec.Anlog | 114 | $20K |
| Mirabegron | 143 | $16K |
| Cenobamate | 39 | $16K |
| Ipratropium/Albuterol Sulfate | 32 | $16K |
Prescribing Profile
Patient Profile
79
Avg Age
70%
Female
2.45
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About